Objectives: Robotic-assisted radical prostatectomy (RARP) has been shown to reduce blood loss, peri-operative complications and length of stay when compared to open radical prostatectomy (ORP). We sought to determine whether the reported benefits of RARP over ORP translate to obese patients. Patients and Methods: We utilized the 2009-2010 Nationwide Inpatient Sample to identify all obese men with prostate cancer who underwent ORP and RARP. Our primary outcome was the presence of a peri-operative adverse event (i.e. blood transfusion, complication, prolonged length of stay). We fit multivariable logistic regression models to examine whether RARP in obese patients was independently associated with decreased odds of all three outcomes. Results: We identified 9,108 obese patients who underwent radical prostatectomy. On multivariable analysis, the use of RARP in the obese population was not independently associated with decreased odds of developing a peri-operative complication (OR = 0.81, CI: 0.58-1.13, p = 0.209). RARP was, however, associated with decreased odds of blood transfusion (OR = 0.17, CI: 0.10-0.30, p < 0.001) and prolonged length of stay (OR = 0.28, CI: 0.20-0.40, p < 0.001). Conclusion: Our findings suggest that in obese patients, the use
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Introduction
With an expected incidence of 233,000 new cases in 2014, prostate cancer is the most common solid organ malignancy in men in the United States [1] . One in six men will develop the disease during their lifetime and many of these men will choose the radical prostatectomy for treatment. In the last decade, the use of robotic-assisted radical prostatectomy (RARP) has surpassed that of open radical prostatectomy (ORP) [2, 3] . Without data from randomized controlled trials, the benefits of RARP over ORP have largely been described using single institution and administrative claims-based studies. Despite the inherent limitations of observational study designs, the evidence suggests that RARP may be associated with decreased blood loss, peri-operative complications, and length of stay [2] [3] [4] .
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Obesity affects nearly 40% of adults in the United States and the operative interventions and perioperative care of these patients can be challenging [5] [6] [7] [8] . Comorbid conditions, including diabetes mellitus, hypertension, dyslipidemia, heart disease and obstructive sleep apnea, may increase the risk of adverse peri-operative events and prolong hospital stay [9] [10] [11] . Whether the known benefits of RARP translate to the obese population remains largely unknown.
Many previous investigators have studied the clinical and surgical outcomes of obese patients undergoing both RARP and ORP [5, 8, [12] [13] [14] [15] [16] [17] . Obese patients are at risk for unfavorable pathologic findings, increased risk of progression towards castrate-resistant disease and increased mortality [18] [19] [20] . In single institution studies, obesity has been associated with higher rates of per-operative complications, urinary incontinence, vesico-urethral strictures, and longer operative time when compared with non-obese populations [17, 21, 22] . While single institution studies provide granular patient level data, administrative claims-based analyses allow for the comparison of interventions across hundreds of hospitals and surgeons. Furthermore, large datasets allow for the comparison of rare events (e.g. stroke, acute myocardial infarction).
This study had two objectives. First, we used the Nationwide Inpatient Sample (NIS), an administrative claims-based dataset, to compare three peri-operative adverse events including blood transfusions, complications and prolonged length of stay (pLOS) of obese patients undergoing RARP versus ORP. Second, we used multivariable analysis to determine whether RARP decreased the odds of developing these three adverse events in the obese population.
Patients and Methods

Dataset
We used the 2009-2010 NIS for this analysis. Part of the Healthcare Cost and Utilization Project the NIS is maintained by the Agency for Healthcare Research and Quality (AHRQ) and includes all-payer data drawn from hospitals in 44 states. For each year of the dataset, 20% of participating hospitals are randomly sampled and all discharge data from these selected hospitals are included in that year's dataset. Specifically, hospitals are stratified by state and three-digit zip code and a systematic random sample is drawn to ensure geographic variability and no bias in the type of hospital (e.g. teaching versus non-teaching).
We selected 2009 and 2010 as our study period because, prior to October 2008, robotic procedures could not be distinguished from laparoscopic procedures by using billing codes. We used the methods recommended by Healthcare Cost and Utilization Project to adjust for the sampling used to construct the dataset [23] . The NIS has been widely used by researchers in urology and other surgical fields to compare peri-operative outcomes [2, 24, 25] . Because this study uses publically available data, the study is exempt from institutional review board approval.
Identification of Patient Cohort and Characteristics
Using International Classification of Disease (ICD), 9th revision, Clinical Modification (ICD-9) procedure and diagnostic codes, we first identified all men with prostate cancer (ICD-9 185.0) who were treated with radical prostatectomy (ICD-9 60.5). Next, if the selected patients had a robotic modifier code (ICD-9 17.42) associated with the prostatectomy procedure code, they were categorized in the RARP group. All others were considered as ORP. Finally, we selected only patients who had obesity or morbid obesity listed as a comorbidity. To do so, we used relevant ICD-9 codes that have been previously identified by AHRQ to identify obese patients (ICD-9 278.0, 278.00, 278.01) [26] [27] [28] [29] [30] . In addition, we substratified our population according to severity of obesity (morbid obesity ICD-9 278.01). The ICD-9 codes used for obesity are not necessarily associated with a specific body mass index. Patient characteristics included age (category: ≤ 45, 46-55, 56-65, 66-75, ≥ 76 years), race (white, black, other) and year of treatment. Median income was classified into four groups: (1) < $ 25,000, (2) $ 25,000-34,999, (3) $ 35,000-44,999, and (4) ≥ $ 45,000 [19] . Insurance status was based on the expected primary payer, and included Medicare, Medicaid, private insurance, and other (e.g. the uninsured).
We calculated the Charlson Comorbidity Index for each patient using secondary diagnosis codes using a validated algorithm published by Deyo et al. [31] and categorized as 0-1, 2, ≥ 3.
Hospital Characteristics
Hospital characteristics include teaching status, location and hospital volume. Institutional teaching status was obtained from the American Hospital Association Survey of Hospitals. A hospital is considered to be a teaching hospital if it is a member of the Council of Teaching Hospitals; it has an American Medical Association-approved residency program or has a ratio of full-time equivalent interns and residents to beds of 0.25 or higher. Hospital location was defined as urban or rural. Hospital volume was defined according to previously described methodology as the annual number of obese patients with prostate cancer that underwent radical prostatectomy [32, 33] .
Identification of Outcomes
Our primary outcomes of interest were blood transfusions, peri-operative complications, and pLOS (length of stay (LOS) > 2 days). These outcomes were selected because they are commonly used to compare RARP and ORP [2, 3] . We used previously published methodology to identify patients who required a blood transfusion (ICD-9 99.02 and 99.03) and those who had a peri-operative complication [2] . Peri-operative complications were identified using related ICD-9 codes and grouped into categories (any, intraoperative, cardiac, respiratory, gastrointestinal, genitourinary, neurological vascular, infectious, miscellaneous) .
LOS is calculated by subtracting the admission date from the discharge date [34] . Same-day stays, coded as 0, were excluded from current analysis. In-hospital mortality information is coded from disposition of patient. Patients with missing or invalid LOS or in-hospital mortality status were not considered within the current study.
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Statistical Analysis
Frequencies and proportions were generated for categorical variables; medians and interquartile ranges were generated for continuously coded variables. The Mann-Whitney-U and the Chi-square test were used to assess differences in medians and proportions respectively. We then fit multivariable logistic regression models adjusted for severity of obesity, comorbidity, age, race, median income, insurance status, teaching hospital status, geographic region and HV to examine whether RARP in obese patients was associated with decreased odds of blood transfusion, any peri-operative complication or pLOS. In addition, we adjusted for clustering of patients within hospitals by fitting generalized estimating equations. All tests were two-sided with a statistical significance of p < 0.05. Analyses were conducted using SPSS Statistics (Version 20.0, IBM, Chicago, IL) and the R statistical package v.2.13.1 (R Foundation for Statistical Computing).
Results
We identified 9,108 obese patients (in our weighted population) who underwent radical prostatectomy from January 2009 to December 2010. All of these patients had obesity (7,266) or morbid obesity (1,842) listed as a comorbidity. For the remainder of the analysis, patients with any form of obesity are referred to as "obese". Among all patients, 5,503 (60.4%) underwent RARP and 3,605 (39.6%) underwent ORP. Table 1 and 2 describe the main characteristics of our patient cohort and hospitals in our study. Table compares hospital level characteristics of centers that were included in our study, stratified by surgical modality. RARP = Robotic-assisted radical prostatectomy; ORP = open radical prostatectomy. Table 3 describes the rate of organ-specific peri-operative adverse events stratified by RARP and ORP. We found that patients that underwent ORP had a higher rate of any complication occurring compared to those that underwent RARP (21.3% vs. 16.6%, p < 0.001). Specifically, ORP patients had higher rates of intraoperative (3.5% vs. 2.1%, p < 0.001), respiratory (2.4% vs. 1.7%, p = 0.040), genitourinary (7.1% vs. 6.1%, p = 0.049) and infections (0.8% vs. 0.3%, p < 0.001) complications. Obese patients undergoing RARP had decreased rates of pLOS (46.3% vs. 19.4%, p < 0.001) and had a decreased rate of blood transfusion (11.2% vs. 2.2%, p < 0.001).
Selected results from multivariable models are displayed in Table 4 . After adjusting for patient and hospital characteristics we found that morbid obesity was independently associated with increased odds of any complication (OR = 1.61, CI: 1.18-2.18, p = 0.002), blood transfusion (OR = 2.09, CI: 1.08-4.05, p = 0.028) and pLOS (OR = 1.51, CI: 1.05-2.17, p = 0.028). The use of robotic surgery in the obese population was not independently associated with decreased odds of any complication (OR = 0.81, CI: 0.58-1.13, p = 0.209). Robotic prostatectomy was, however, associated with decreased odds of blood transfusion (OR = 0.17, CI: 0.10-0.30, p < 0.001) and pLOS (OR = 0.28, CI: 0.20-0.40, p < 0.001).
Discussion
In this study, RARP was performed more commonly than ORP in obese men. After adjusting for patient and hospital characteristics, we found that obese patients undergoing RARP had reduced odds of having prolonged LOS and receiving a blood transfusion relative to obese patients undergoing ORP. The odds of developing a perioperative complication, however, were similar between obese patients who underwent RARP and ORP. These findings suggest that RARP can be safely performed in obese men and may decrease blood loss and length of stay.
RARP has been previously compared to ORP using secondary data analysis [2] [3] [4] . In these studies, RARP has been found to result in fewer peri-operative complications, shorter lengths of stay, and decreased blood loss. Our study builds on this existing evidence by investigating whether the known benefits of RARP translate to a clinically challenging population (i.e. obese men). While we found that previously reported blood loss and LOS benefits of RARP are consistent for obese men, RARP did not reduce the odds of peri-operative complications in this population. Our findings are partially consistent with single institution studies that have evaluated RARP in the obese population [8, 14, 16] . While RARP appears to consistently yield reduced blood loss and length of stay in all studies, RARP reduces the rate of complications in some of these studies. This inconsistency may be partly due to the fact that single institution studies often reflect outcomes of high volume surgeons while a national database captures the outcomes of surgeons across the country with a wide range of experience in robotics.
Our study has several limitations. First, obesity is likely under-coded in administrative claims. Therefore, our results may be biased in an unknown direction by the exclusion of some obese patients. The approach we used to identify obese patients, however, was developed by the U.S. AHRQ. We believe while the AHRQ-defined comorbidity measure for obesity may have not been highly sensitive, it was highly specific for identifying obese patients and has been widely used by researchers in many fields [26] [27] [28] [29] [30] . Second, our measure of obesity did not stratify patients by body mass index (BMI). Our dataset did not include height and weight measures, and while ICD-9 modifier codes exist for BMI, these codes are not frequently reported. While using BMI to stratify patients Ellimoottil/Roghmann/Blackwell/Kadlec/ Greco/Quek/Sun/Trinh/Gupta may have provided greater nuance to our findings, the use of BMI to define obesity is not without limitations in some patients (e.g. muscular men). Finally, the use of an administrative claims database (i.e. the NIS) to compare interventions has many inherent limitations (e.g. no oncologic information, coding of complications may differ across hospitals, surgeon characteristics and operative time are unknown). Oncological characteristics, such as presence of locally advanced disease or extent of lymph node dissection, will undoubtedly affect perioperative outcomes. Moreover, it is plausible, however, that patients who suffered an adverse event did not have that adverse event coded. For example, if a patient had a blood transfusion, but that transfusion was not coded in their chart, then we would not know if a transfusion was given. There is no way to quantify this misclassification bias that is present in all studies that use administrative claims. The use of a population-based database in the context of this study, however, has advantages over the existing single institution studies. For one, our dataset allows us to compare the two surgical modalities across hospitals and surgeons across the country. Outcomes from single institution studies are often limited to high volume surgeons and centers, which limits their generalizability. Also, rare events are better captured in large datasets. For example, in one single surgeon study comparing RARP and ORP in obese men, no intraoperative complications and only four total complications were reported in both groups [14] .
These limitations notwithstanding, our findings have several implications. For policymakers and payers, the finding that RARP reduces blood transfusion and length of stay even in obese patients offers a better understanding of the value in robotic surgery in challenging patients. For urologists, the finding that ORP and RARP have similar peri-operative complication rates in this subpopulation implies that RARP and ORP remain interchangeable and the surgeon's comfort level with either the procedure should dictate ultimate choice of surgical approach. Finally, for patients with obesity and prostate cancer, the broad findings suggest that both surgical approaches are feasible and safe.
Our collective findings suggest that RARP has a similar complication profile with reduced LOS and blood transfusion rates. Future research in this area should focus on comparing RARP and ORP in regards to oncologic and functional outcomes in obese patients using cancer registries (e.g. surveillance, epidemiology, and end results). Ultimately, the value of RARP in the obese population will depend on a relative balance between peri-operative, oncologic, functional and economic outcomes. 
